<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002635</url>
  </required_header>
  <id_info>
    <org_study_id>2019LEFT001</org_study_id>
    <nct_id>NCT04002635</nct_id>
  </id_info>
  <brief_title>Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)</brief_title>
  <acronym>LEFT</acronym>
  <official_title>Endometrial Preparation Using Letrozole Compared to Artificial Cycle for Frozen Embryo Transfer in PCOS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRG UZ Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CRG UZ Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To offer patients with oligomenorrhoea or amenorrhoea an alternative to frozen embryo
      transfer in an artificial cycle, endometrial preparation using letrozole may be a valuable
      option. Letrozole, a potent, reversible nonsteroidal aromatase inhibitor with relatively
      short half-life, can successfully induce ovulation without any adverse anti-estrogenic
      effects and thus without affecting the endometrium. The use of letrozole typically results in
      monofollicular growth and this reduces the effect of supraphysiological levels of estrogen on
      the endometrium and embryo. The purpose of this study is to compare a frozen-thawed embryo
      transfer in an artificial cycle with a letrozole-induced ovulatory cycle, specifically in
      PCOS patients. The primary outcome is early pregnancy loss.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early pregnancy loss</measure>
    <time_frame>12 weeks after frozen embryo transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cancellation rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of visits to the clinic</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness on the day of planning of FET</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical and clinical pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal birth weight</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>term of delivery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypertensive disorders of pregnancy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>IVF</condition>
  <condition>Ovulation Disorder</condition>
  <arm_group>
    <arm_group_label>Hormonal Replacement Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial preparation of the endometrium using estradiol valerate 2mg 3x/day, and vaginal micronized progesterone 2x 400mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using letrozole for ovulation induction before planning the frozen embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole ovulation induction</description>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol valerate</intervention_name>
    <description>hormonal replacement therapy</description>
    <arm_group_label>Hormonal Replacement Therapy</arm_group_label>
    <other_name>progesterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than or equal to 18 and less than or equal to 40

          -  BMI more than or equal to 18 and less than or equal to 35

          -  Diagnosis of PCOS according to Rotterdam criteria

          -  Normal gynaecological ultrasound &lt; 6 months before inclusion

          -  Signed informed consent form

          -  Day 5 or 6 frozen-thawed embryo transfer, blastocyst stage

        Exclusion Criteria:

          -  Recurrent implantation failure

          -  Recurrent miscarriage

          -  Presence of adenomyosis

          -  Untreated intrauterine pathology

          -  rAFS (revised American Fertility Society) Grade III or IV endometriosis

          -  Hydrosalpinx

          -  In vitro maturation (IVM)

          -  Untreated autoimmune disorders

          -  (History of) malignancy

          -  Allergy or reaction to the use of progynova, utrogestan and/or letrozole in the past

          -  Pre-implantation genetic testing (PGT)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liese Boudry, Dr</last_name>
    <phone>02 474 98 57</phone>
    <email>liese.boudry@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel De Vos, Prof. Dr.</last_name>
    <phone>02 474 40 07</phone>
    <email>michel.devos@uzbrussel.be</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CRG UZ Brussel</investigator_affiliation>
    <investigator_full_name>Liese Boudry</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>frozen embryo transfer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing with other study site, UZ Gent</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

